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relationship between the EQD2 for both treatment locations 
(CRT, SDRT) and the occurrence of a first CVA was assessed. 
Results: After a median time of 24.9 years from the primary 
diagnosis and at a median attained age of 31.2 years, 28 
survivors had a first CVA. Of them, 18 (64.3%) had ischemic 
events (Grade 3-4), and 10 (35.7%) had hemorrhagic events 
(Grade 2-5). One survivor was not treated with CRT nor with 
SDRT. Subsequently, two survivors had a second, and one a 
third CVA. The 35-year cumulative hazard in survivors treated 
with CRT only was 14.2% (95%CI, 3.5-24.9%), in survivors 
treated with SDRT only 6.8% (95%CI, 0-13.7%), and in 
survivors who received both CRT and SDRT 24.3% (95%CI, 6.7-
41.8%) (Figure). The Cox analyses showed that both 
treatment locations significantly increased the risk of CVA in 
a dose-dependent manner (HRCRT 1.02 Gy-1; 95%CI, 1.01-1.03, 
and HRSDRT 1.04 Gy-1; 95%CI, 1.02-1.05). 
 
 
Figure. Cumulative hazards and 95%CIs for the first CVA ≥5 
years after the primary cancer diagnosis in survivors treated 
with CRT only, SDRT only, both CRT and SDRT, and in 
survivors who had no CRT and no SDRT. 
Note: The SDRT only group consisted of 95 survivors; SDRT 
treatment could not be confirmed for 3 survivors, leaving 92 
survivors for analysis. 
Conclusions: Our results demonstrate that childhood cancer 
survivors treated with CRT and/or SDRT have an increased 
risk of CVAs as compared with survivors who had no CRT and 
no SDRT. Thirty-five years after treatment, almost 1 in 4 
childhood cancer survivors treated with both CRT and SDRT 
experience a symptomatic CVA. In addition, these radiation-
associated CVAs occur at a very young age. Therefore, 
continuing follow-up with a focus on tailored preventive 
strategies to reduce the risk of CVAs in this young population 
deserves special attention. 
   
OC-0342   
A UK national review of radiotherapy treatment plans for 
paediatric medulloblastoma in cases of neurotoxicity  
H. Mayles1, A. Baker2, N. Thorp2, J. Hayden3, G. Horan4 
1The Clatterbridge Cancer Centre - Wirral NHS Foundation 
Trust, Physics Department, Bebington Wirral, United 
Kingdom  
2The Clatterbridge Cancer Centre - Wirral NHS Foundation 
Trust, Radiotherapy Department, Bebington Wirral, United 
Kingdom  
3Alder Hey Children's Hospital NHS Foundation Trust, 
Oncology Department, Liverpool, United Kingdom  
4Addenbrooke's Hospital NHS Foundation Trust, Radiotherapy 
Department, Cambridge, United Kingdom  
 
Purpose/Objective: Paediatric metastatic medulloblastoma 
requires intensive treatment for the best results. Since 2007 
the majority of UK centres used the Milan strategy (High dose 
Chemotherapy and twice daily Radiotherapy) to treat these 
patients. There were some reported cases of profound 
neurotoxicity and a review of plans and treatment method 
was done in order to check whether radiotherapy had 
contributed to the toxicity. 
Materials and Methods: Patients with Grade 3-4 
neurotoxicity, treated between 2008 and 2014, were 
identified and the toxicities classified into global and 
myelitis. Plan data (CT planning scans, Plans and Dosegrids) 
for the CranioSpinal (CNS) phase 1 and the Posterior Fossa 
Boost (PFB) phase 2 , was collected and imported into Eclipse 
(Varian). The dosimetry was reviewed for individual and 
summed phases. Where possible MR images showing myelitis 
were blended with the dose distribution on the CT scan. A 
questionnaire was circulated around all Centres to establish 
the RT technique and immobilisation used. 
Results: 10 cases (8 male, all under 12 years), from 6 Centres 
were reviewed. All the children had a poor response to 
induction chemotherapy and received thiotepa as part of 
their high dose chemotherapy regime. The CNS dose was 
39Gy in 30 Fr for 9 cases and 31.2 Gy in 1 Fr for 1. All 
received a PFB to a dose of 59.7 – 60 Gy. All Centres used a 
conformal Linac based technique with opposed Head fields 
matched to posterior Spine fields, and a shifting gap. 5 out of 
6 centres used a supine technique. 1 Centre used VMAT for 
the PFB, others a 3DCRT plan. 1 Centre checked plans using 
summed doses, others checked each phase separately. The 
myelitis occurred in the PFB volume and it was noted that for 
these patients the C1 summed dose was >62 Gy, although less 
than 63Gy (105%), see Fig 1.  
 
 
Conclusions: There was no evidence of radiation techniques 
contributing to neurotoxicity. However when the Milan 
protocol was adapted for the UK, there was no involvement 
of physics and certain details of the treatment were 
different, in particular that in Milan the PFB PTV would not 
include the spinal cord. This review also highlighted the 
importance of planning and summing both phases in order to 
assess the combined dose. It is recommended that special 
attention is paid to the cervical spinal cord dose with a strict 
dose constraint of 61Gy. Lessons learnt from this review 
highlight the importance of sharing experience both 
nationally and internationally especially for rare tumours. 
   
 
Debate: SBRT / oligometastatic disease: Oligomets then 
SABR is standard of care  
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Stereotactic Body Radiotherapy (SBRT) is today the accepted 
standard of care for early stage non-small cell lung cancer if 
